PFE Q1 Earnings Call: Revenue Misses, Margin Expansion, and Focus on Pipeline Productivity

Global pharmaceutical company Pfizer (NYSE: PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.92 per share was 36.1% above analysts’ consensus estimates.

Is now the time to buy PFE? Find out in our full research report (it’s free).

StockStory’s Take

Pfizer’s first quarter of 2025 reflected continued headwinds in top-line growth, driven by declining demand for key COVID-related products and the impact of U.S. policy changes such as the IRA (Inflation Reduction Act) Medicare Part D redesign. Management attributed the revenue decline to lower sales of Paxlovid and vaccine products, as well as heightened competition in certain therapeutic areas. CEO Albert Bourla highlighted ongoing efforts to prioritize high-value R&D projects and optimize the company’s product portfolio, noting, “We are intensifying our rigorous commercial assessment and portfolio prioritization from early clinical development.”

Looking forward, management reaffirmed its full-year guidance, placing emphasis on disciplined cost management, operational efficiency, and a sharpened focus on pipeline execution. CFO Dave Denton stated, “Our productivity improvement programs continue to drive a more efficient organization enhanced by our strong operating margins in the quarter.” Management also discussed the company’s approach to navigating tariff uncertainty and potential regulatory changes, emphasizing a strategy rooted in flexibility and capital discipline.

Key Insights from Management’s Remarks

Management focused on pipeline reprioritization, operational efficiency, and market-specific trends as central to Pfizer’s Q1 performance and strategic direction.

• R&D Pipeline Realignment: Pfizer is accelerating portfolio optimization by discontinuing lower-priority programs, such as Daniel Bipro, and focusing on potential blockbuster assets, particularly in cardiometabolic and obesity-related treatments. The company is exploring both internal and external opportunities in this area, including partnerships and acquisitions.

• Leadership and Organizational Changes: Recent appointments to the R&D leadership team—such as Patrizia Cavazzoni (Chief Medical Officer), Jeff Lagos (Chief Oncology Officer), and Jim List (Chief Internal Medicine Officer)—reflect a commitment to therapeutic area expertise and pipeline advancement.

• Key Product Trends: Commercial performance was mixed, with growth in oncology (e.g., PADCER, LoBrena), rare disease (e.g., Vyndaqel/Vyndamax), and immunology (e.g., Cibinqo) offset by continued declines in Paxlovid and Eliquis sales. International markets provided some offset to U.S. softness, particularly in vaccines and specialty medicines.

• Cost Management Initiatives: Ongoing cost realignment and productivity programs delivered a 12% reduction in operating expenses. Management anticipates $4.5 billion in cumulative net cost savings by the end of 2025, with further targeted savings planned through 2027, including digital and automation-driven efficiencies.

• Tariff and Regulatory Uncertainty: Management is closely monitoring potential sector-specific tariffs under the U.S. Section 232 investigation. Contingency planning includes inventory management and leveraging U.S. manufacturing capacity to mitigate possible impacts. The company is also engaged in ongoing dialogue with government stakeholders regarding policy changes affecting pharmaceutical manufacturing and pricing.

Drivers of Future Performance

Management’s outlook for the remainder of the year is shaped by a balance of ongoing cost discipline, targeted investments in pipeline assets, and vigilance regarding external policy risks.

• Focus on High-Value Pipeline Assets: The company is prioritizing late-stage clinical programs, particularly in oncology, cardiometabolic disease, and vaccines. Management expects several phase three readouts and regulatory decisions in 2025 to influence long-term growth.

• Expense Reduction and Margin Expansion: Productivity initiatives—such as digital transformation, business process simplification, and manufacturing optimization—are expected to support operating margin improvement, even as revenue faces pressure from loss of exclusivity and policy headwinds.

• Navigating Policy and Tariff Risks: Management highlighted the potential for new U.S. trade and tariff actions to affect the cost structure and supply chain. The company is preparing mitigation strategies, but acknowledges that policy developments could introduce further uncertainty to forecasting and capital allocation.

Top Analyst Questions

• Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff and cash flow uncertainty. CFO Dave Denton reiterated the company’s commitment to the dividend, citing ongoing productivity improvements and margin expansion as key supports.

• Tim Anderson (Bank of America): Inquired about the likelihood and potential timing of sector-specific tariffs under Section 232, as well as the distinction between friendly and adversary countries. CEO Albert Bourla explained the focus on national security and ongoing engagement with U.S. authorities to address concerns.

• Evan Seigerman (BMO Capital Markets): Sought insight into Pfizer’s desired characteristics for future obesity assets following the discontinuation of Daniel Bipro. Chief Scientific Officer Chris Boshoff described a focus on differentiated, orally available candidates with improved tolerability and accessibility.

• Geoff Meacham (Citi): Asked about business development priorities and incentives for U.S. manufacturing expansion. Management emphasized building sustainable franchises and noted tax and regulatory clarity as potential drivers for domestic investment.

• Trung Huynh (UBS): Questioned the pace of cost savings realization and the impact of the current macro environment on business development activity. Management indicated that most incremental savings will materialize in 2026–2027, and that opportunity pursuit is being calibrated to current valuations and market volatility.

Catalysts in Upcoming Quarters

As we look ahead, the StockStory team will be tracking (1) progress on phase three clinical trial readouts and regulatory milestones in oncology, vaccines, and obesity, (2) the effectiveness of cost reduction and productivity programs in supporting operating margin targets, and (3) developments around U.S. tariff policies and their impact on Pfizer’s manufacturing footprint and supply chain resilience. Execution in these areas will be crucial to sustaining long-term growth and shareholder value.

Pfizer currently trades at a forward P/E ratio of 7.7×. At this valuation, is it a buy or sell post earnings? The answer lies in our free research report.

The Best Stocks for High-Quality Investors

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.